Spectrus

Executive Summary

Spectrus is a US-based contract research organization (CRO) headquartered in Cambridge, MA, specializing in mass spectrometry services for the biotech and life sciences industries. Founded in 2018, the company provides end-to-end LC/MS support, including method design, sample processing, data analysis, and regulatory-compliant reporting. With deep expertise in 'omics and biomolecule characterization, Spectrus helps clients accelerate discovery and make data-driven decisions. Its focus on high-quality, reliable mass spectrometry positions it as a valuable partner for both early-stage biotechs and established pharmaceutical companies seeking to outsource analytical workflows. As the demand for specialized CRO services grows with the expanding biotech sector, Spectrus is well-positioned to capture market share. Its competitive advantages include a strong technical team, proximity to the vibrant Cambridge life sciences ecosystem, and a commitment to regulatory compliance. While the company remains private and has not disclosed funding or valuation, its service-oriented model generates recurring revenue. Future growth likely hinges on capacity expansion, technology upgrades, and strategic partnerships with drug developers. The CRO space is fragmented, and Spectrus's niche in mass spectrometry could drive steady, albeit moderate, growth.

Upcoming Catalysts (preview)

• Q3 2026Expansion of high-resolution mass spectrometry capabilities70% success
• Q4 2026Strategic partnership with a major pharmaceutical company50% success
• Q1 2027Opening of a new laboratory facility to increase capacity60% success